Lexicon Pharmaceuticals, Inc. LXRX
1.75 USD -0.04 (-2.23%)
Regular-session close
1.77 +0.02 +1.14%
Pre-market · Nov 17, 8:47 AM ET
1.73 Day range 1.84
1.10 52-week range 2.68
- YTD
- +52.17%
- 1 year
- +17.45%
News
globenewswire.com Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London THE WOODLANDS, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced that Company management will…benzinga.com Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4 Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $3.1 to $3.4.
benzinga.com Lexicon Pharma Presents New Data Highlighting Cardiovascular Effects Of Dual SGLT1/2 Inhibitor, Sotagliflozin, At AHA Scientific Sessions 2026 -- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions ---- Study in living human heart tissue…
benzinga.com Lexicon Pharmaceuticals Q3 2026 Earnings Call Transcript Lexicon Pharmaceuticals (NASDAQ:LXRX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…benzinga.com Lexicon Pharmaceuticals Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $11.250M Beat $4.142M Estimate Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 25 percent increase over losses of…
benzinga.com Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing…
benzinga.com Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways -- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of…
